GSK’s Lamictal Adds Indication As Add-On Therapy For Grand Mal Seizures
This article was originally published in The Pink Sheet Daily
Executive Summary
Next in the pipeline for GSK’s epilepsy franchise is an XR formulation for once-daily dosing.
You may also be interested in...
GSK’s Lamictal Extended Release Is “Approvable” At FDA
Agency is seeking additional analyses of data used to support the sNDA for the epilepsy drug.
GSK’s Lamictal Extended Release Is “Approvable” At FDA
Agency is seeking additional analyses of data used to support the sNDA for the epilepsy drug.
Lamictal Pregnancy Monitoring Will Continue Following “FDA Alert”
FDA issues leaflet to physicians and healthcare professionals regarding potential oral clefts in children exposed to Lamictal during first trimester of pregnancy.